Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Transcend Therapeutics Inc.

Division of AJL Ophthalmic SA

Latest From Transcend Therapeutics Inc.

Amazon Versus Biotech: How The IPO Class Of '97 Worked Out

Life sciences investors pumped around $15 billion into 175 biotech, medtech and diagnostics firms that went public during the 2014–16 IPO window. To understand what may be in store for those firms and their backers, In Vivo reexamines the fate of a previous generation of companies, the IPO Class of 1997.

Financing Growth

Playing the High-Stakes Pharma Game, Part I

The rise in valuations of Big Biotech is due in large part to the fact that they're seen as affordable acquisition candidates for Big Pharmas in search of late-stage products. The plethora of early-stage biotech consolidation is, in contrast, generally a choice of last resort for otherwise unfinanceable companies who also can't sign worthwhile pharma deals. But the attention on late-stage programs offers opportunities for companies, like Pfizer, to strike platform technology deals which transfer technology, royalty free, from biotech to drug firm. The deals aren't cheap but these structures, impossible when platform deals were popular, allow Pfizer much greater research freedom.
BioPharmaceutical Strategy

Spinning off Small Companies

The post-merger cutting room floor creates a great source of new companies and products--it’s good asset management for Big Pharma, and it’s good for medical entrepreneurs. But culturally and structurally, most large companies just can’t go along with the business logic of spin-offs. Technology that does get spun off is most often completely peripheral to the parent’s business--e.g., in vitro diagnostic applications or software and equipment systems from a drug company.
Strategy

Cornell University

Cornell tries to turn Ithaca into a Cambridge-like hub of tech transfer.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • AJL Ophthalmic SA
  • Senior Management
  • B. N Harvey, SVP, Corp. Dev.
    John J Whalen, MD, EVP & CSO
  • Contact Info
  • Transcend Therapeutics Inc.
    Phone: (617) 374-1200
    640 Memorial Dr.
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register